Watertown, Mass. — Seismic Therapeutic has named Dr. Sophie Jones as its new Chief Financial Officer, effective June 18, 2025. The appointment brings a rare combination of financial acumen and clinical expertise to the immunology-focused biotech firm, as it continues to advance its lead drug candidates into clinical trials.
Dr. Jones joins Seismic following a distinguished career in healthcare investment banking and medicine. Most recently, she served as Managing Director in Healthcare Investment Banking at J.P. Morgan, where she advised life sciences companies on over $250 billion in equity financing and M&A transactions. Her previous experience includes a role at Centerview Partners focused on healthcare mergers and acquisitions.
“Sophie brings a unique blend of deep financial expertise and medical training that will be instrumental as Seismic moves into its next stage of growth,” said Jo Viney, Ph.D., Founder, President, and CEO of Seismic Therapeutic. “Her leadership comes at a critical time as we push forward our two lead biologic programs in the clinic and continue to develop our machine learning-driven immunology pipeline.”
Trained as a physician scientist, Dr. Jones completed her medical education with honors at Boston University School of Medicine and her undergraduate degree at Yale University. She also completed surgical training and held a chief fellowship in heart-lung transplantation at Columbia University’s New York-Presbyterian Hospital.
“This is an exciting time to join Seismic,” said Dr. Jones. “The company’s integration of machine learning into biologics drug development through its IMPACT platform is generating a robust pipeline, and I’m eager to help support this mission of delivering innovative therapies for patients with autoimmune and allergic diseases.”
Her appointment reflects Seismic’s commitment to strengthening its executive leadership as it scales its operations and advances toward becoming a clinical-stage biotechnology leader in immunology.
